United Kingdom (UK) – Healthcare, Regulatory and Reimbursement Landscape

All the vital news, analysis, and commentary curated by our industry experts.

$1995

Buy Report Download FREE Resources

Published: June 30, 2021 Report Code: GDHC0053CHR-ST

Report Overview
Table of Contents
Table
Figures

GlobalData, the industry analysis specialist, has released its latest report, "United Kingdom (UK) – Healthcare, Regulatory and Reimbursement Landscape". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in the UK. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

The UK healthcare market is one of the most promising market globally, with universal health coverage and a strong focus on R&D in the field of genomics, artificial intelligence (AI), early-stage diagnostics, and big data. The UK pharmaceutical market increased from £13.77B in 2012 to £21.84B in 2019 at a Compound Annual Growth Rate (CAGR) of 6.8%. In terms of US Dollars, the market increased from $21.76B in 2012 to $29.42B in 2019 at a CAGR of 3.8%. It is forecast to reach about $35.52B in 2025. The key drivers contributing to the growth of the UK pharmaceutical market are universal healthcare coverage, the growing elderly population, increased access to healthcare services, high disease burden, and innovation in personalized medicines. However, the increased focus on generic drugs will be a barrier to the pharmaceutical market.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the UK, and includes:

An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers

Profiles and SWOT analyses of the major players in the pharmaceutical market: Pfizer, Novartis, GSK, AstraZeneca, and Merck

Profiles and SWOT analyses of the major players in the medical device market: Abbott, Medtronic, Roche Diagnostics, Siemens Healthineers, and Smith & Nephew

An insightful review of the COVID-19 epidemiology, COVID-19 impact, and developments in healthcare market, HealthTech landscape, reimbursement, and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices

Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure, and healthcare expenditure

An overview of the opportunities for and challenges to growth in the UK healthcare market

Reasons to Buy

This report will enhance your decision-making capability by allowing you to:

Develop business strategies by understanding the trends shaping and driving the UK’s healthcare market

Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the UK’s healthcare market in the future

Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

1. Table of Contents

1.1List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights – Facts about the UK Healthcare Market

2.3 Key Highlights: Healthcare Startups in the UK

2.4 Key Events: UK Healthcare Timeline, 2014-2021

2.5 Key Events: UK Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2019-2020

2.7 Key Events: Mergers and Acquisitions

2.8 Country Profile, UK, 2020

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, UK

3.5 Pharmaceutical Market – Market Segments

3.6 Major Therapeutic Areas, UK

3.7 COVID-19 Epidemiology, UK

3.8 COVID-19 Impact and Developments in the Healthcare Market, UK

3.9 COVID-19 Clinical Trials Landscape, UK

3.10 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, UK, 2020-2021

6.2 Deal Analysis: Medical Device Market, UK, 2020-2021

7. HealthTech Landscape

7.1 HealthTech Landscape, UK

7.2Adoption of Technology in Healthcare, UK

7.3 HealthTech Deals Landscape, UK

7.4 Key HealthTech Deals, UK

7.5Key Developments: Collaborations and Deals Toward Digital Health, UK

7.6Key Developments: National AI Strategy, UK

7.7 Regulatory Scenario Covering Use of Technology in Healthcare, UK

7.8 HealthTech Landscape: Benefits and Risks, UK

8. Market Access

8.1 Overview of Healthcare System, UK

8.2 Reimbursement Process, UK

8.3 Overview of Insurance Providers, UK

8.4 Healthcare Spending and Consumer Price Index, UK

8.5 Pricing Policies, UK

8.6 Regulatory Landscape, UK

8.6.1 Overview of Regulatory Agencies

8.6.2 Marketing Authorization for Pharmaceutical Products, UK

8.6.3 Marketing Authorization for Biosimilars, UK

8.6.4 Marketing Authorization for Medical Devices, UK

8.6.5 Intellectual Property Rights, Patent, UK

8.6.6 Intellectual Property Rights, Trademark, UK

8.6.7 Clinical Trial Regulation, UK

8.6.8 Pharmaceutical Clinical Trials Landscape, UK

8.6.9 Medical Devices Clinical Trials Landscape, UK

8.6.10 Pharmaceutical Advertisement Regulations, UK

8.6.11 Pharmacy Regulations, UK

8.6.12 Labeling and Packaging Regulations, UK

8.6.13 Post-Brexit Impact on UK Healthcare Regulatory Landscape, UK

9. Country Healthcare Landscape

9.1Healthcare Policy Highlights, UK

9.2 Healthcare Facilities, UK

9.3 Healthcare Parameters, UK

9.4 Life Expectancy and Immunization Rate, UK

9.5 Environmental Health, UK

9.6 Healthcare Personnel, UK

9.7 Disease Burden, UK

9.8 Healthcare Expenditure, UK

10 Trade Associations, UK

11 Trade Fairs, UK

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: COVID-19 Indicators (Number of Cases), UK and Global, 2020-2021

Table 2: COVID-19 Drugs (by Manufacturer Database), UK and Global, 2020-2021

Table 3: COVID-19 Vaccines Authorized, UK, 2020-2021

Table 4: Medical Devices Market, UK, Major Segments ($B), 2020

Table 5: General Surgery Devices Market, UK, Revenue ($B) and Market Share (%) of Major Companies, 2019

Table 6: Orthopedic Devices Market, UK, Revenue ($B) and Market Share (%) of Major Companies, 2019

Table 7: Cardiovascular Devices Market, UK, Revenue ($B) and Market Share (%) of Major Companies, 2019

Table 8: Wound Care Management Market, UK, Revenue ($B) and Market Share (%) of Major Companies, 2020

Table 9: Anesthesia and Respiratory Devices Market, UK, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 10: Patent Fees, 2020, UK

Table 11: Trademark Fees, 2020, UK

Table 12: Clinical Trials Application Fees, 2020, UK

Table 13: Clinical Trials Application Fees for Medical Devices, 2020, UK

Table 14: Post-Brexit Impact on UK Healthcare Regulatory Landscape, UK, 2021

Table 15: Conferences and Trade Fairs, UK, 2021

Figures

Figure 1: Pharmaceutical Market, UK, Revenue ($B), 2012-2020

Figure 2: Medical Devices Market, UK, Revenue ($B), 2015-2020

Figure 3: Healthcare Start-Ups in the UK, 2020

Figure 4: Country Profile, UK, 2020

Figure 5: Pharmaceutical Market, UK, Revenue ($B), 2012-2019

Figure 6: Pharmaceutical Market, UK, Revenue Forecast ($B), 2020-2025

Figure 7: Pharmaceutical Exports ($B), UK, 2012-2020

Figure 8: Top Export Partners, UK, 2020

Figure 9: Pharmaceutical Imports ($B), UK, 2012-2020

Figure 10: Top Import Partners, UK, 2020

Figure 11: Pharmaceutical Market, Supply Channel, UK, 2019

Figure 12: Generic Drugs Usage (% Share by Volume), UK, 2011-2019

Figure 13: Generic Drugs Usage (% Share by Value), UK, 2011-2019

Figure 14: NHS Genomic Medicine Centers, UK, 2020

Figure 15: Timeline of Cell and Gene Therapy Policies, UK, 2009-2021

Figure 16: OTC Medicines Market, Major Categories ($M), UK, 2019

Figure 17: OTC Medicines Market, Revenue ($B), UK, 2013-2020

Figure 18: OTC Medicines Market, Major Distribution Channels ($M), UK, 2020

Figure 19: Total Expenditure by Therapeutic Class ($B), UK, 2018

Figure 20: Major Therapeutic Areas by Pharmaceutical Sales (Million Units), UK, 2016-2018

Figure 21: COVID-19 (Number of Cases), UK, 2020-2021

Figure 22: COVID-19 (Number of Deaths), UK, 2020-2021

Figure 23: COVID-19-Related Travel Restrictions, UK, 2020-2021

Figure 24: COVID-19 Fiscal Stimulus Timeline, UK, 2020-2021

Figure 25: Vaccine Doses Administered per 1,000 People, UK, 2021

Figure 26: Top COVID-19 In Vitro Diagnostic Products by Type (Number of Available Marketed Products), UK, 2020-2021

Figure 27: Top COVID-19 IVD Products by Manufacturer (Number of Available Marketed Products), UK, 2020-2021

Figure 28: Top COVID-19 IVD Products by Application (Number of Available Marketed Products), UK, 2020-2021

Figure 29: Top COVID-19 IVD Products by Device Class (Number of Available Marketed Products), UK, 2020-2021

Figure 30: COVID-19 Clinical Trials Count by Phase, UK, 2020-2021

Figure 31: COVID-19 Clinical Trials Count by Trial Status, UK, 2020-2021

Figure 32: Top Five COVID-19 Clinical Trials Sponsors by Count, UK, 2020-2021

Figure 33: Pharmaceutical Market, Major Players, UK, 2020

Figure 34: Medical Devices Market, UK, Revenue ($B), 2015-2020

Figure 35: Medical Devices Market, UK, Revenue Forecast ($B), 2021-2025

Figure 36: Medical Devices Market, Major Segments (%), UK, 2020

Figure 37: General Surgery Devices Market, UK, Revenue ($B), 2017-2025

Figure 38: General Surgery Devices Market, UK, Market Share of Major Players (%), 2019

Figure 39: Orthopedic Devices Market, UK, Revenue ($B), 2017-2025

Figure 40: Orthopedic Devices Market, UK, Market Share of Major Players (%), 2019

Figure 41: Cardiovascular Devices Market, UK, Revenue ($B), 2017-2025

Figure 42: Cardiovascular Devices Market, UK, Market Share of Major Players (%), 2019

Figure 43: Wound Care Management Market, UK, Revenue ($B), 2017-2025

Figure 44: Wound Care Management Market, UK, Market Share of Major Players (%), 2020

Figure 45: Anesthesia and Respiratory Devices Market, UK, Revenue ($B), 2017-2025

Figure 46: Anesthesia and Respiratory Devices Market, UK, Market Share of Major Players (%), 2020

Figure 47: Diagnostic Market, UK, Revenue ($B), 2015-2020

Figure 48: Diagnostic Market, UK, Revenue ($B), 2021-2025

Figure 49: Medical Devices Market, Revenue ($B) of Major Companies, UK, 2019

Figure 50: Deal Value and Deal Count, Pharmaceutical Market, UK, 2020-2021

Figure 51: Deal Value and Deal Count, Quarterly, Pharmaceutical Market, UK, 2020-2021

Figure 52: Deal Value and Deal Count Sub-types, Pharmaceutical Market, UK, 2020-2021

Figure 53: Top Therapy Areas by Deal Value ($B), Pharmaceutical Market, UK, 2020-2021

Figure 54: Top Therapy Areas by Deal Count, Pharmaceutical Market, UK, 2020-2021

Figure 55: M&A Deals by Quarter, Pharmaceutical Market, UK, 2020-2021 (by Value and by Number)

Figure 56: VC Deals by Quarter, Pharmaceutical Market, UK, 2020-2021 (by Value and by Number)

Figure 57: Deal Value and Deal Count, Medical Devices Market, UK, 2020-2021

Figure 58: Deal Value and Deal Count, Quarterly, Medical Devices Market, UK, 2020-2021

Figure 59: Deal Value and Deal Count Sub-types, Medical Devices Market, UK, 2020-2021

Figure 60: Top Equipment Areas by Deal Value ($B), Medical Devices Market, UK, 2020-2021

Figure 61: Top Equipment Areas by Deal Count, Medical Devices Market, UK, 2020-2021

Figure 62: M&A Deals by Quarter, Medical Devices Market, UK, 2020-2021 (by Value and by Number)

Figure 63: VC Deals by Quarter, Medical Devices Market, UK, 2020-2021 (by Value and by Number)

Figure 64: Adoption of Technology in Healthcare, UK, 2020

Figure 65: Deal Value ($B), HealthTech, UK, 2019-2020

Figure 66: Deal Count (Number of Deals), HealthTech, UK, 2019-2020

Figure 67: Recommendations for the Development of UK National AI Strategy, UK, 2020

Figure 68: Overview of Healthcare System, UK, 2020

Figure 69: Overview of Finance Flow, UK, 2020

Figure 70: NHS Departmental Expenditure Limit ($B), UK, 2015-2021

Figure 71: Market Access, Reimbursement Schemes, UK, 2020

Figure 72: OOP Expenditure (% of Health Spending), UK, 2012-2020

Figure 73: Annual Rate of Change (%), Consumer Price Index, Pharmaceutical

Products (Base Year 2015=100), UK, 2013-2020

Figure 74:Market Access, MHRA Structure, UK, 2020

Figure 75: Life Cycle of Medical Device, UK, 2018

Figure 76: App Labelling with UKCA Mark, Medical Device, UK, 2020

Figure 77: Patent Approval Process, UK, 2020

Figure 78: Trademark Approval Process, UK, 2020

Figure 79: Clinical Trial Authorization Application Flowchart, 2019, UK

Figure 80: Clinical Trial Regulation Process for Medical Devices, Market Access, 2020, UK

Figure 81: Pharmaceutical Clinical Trials Count by Trial Status, UK, 2019-2021

Figure 82: Pharmaceutical Clinical Trials Count by Phase, UK, 2019-2021

Figure 83: Pharmaceutical Clinical Trials Count by Indication, UK, 2019-2021

Figure 84: Top Five Pharmaceutical Clinical Trials Sponsors by Count, UK, 2019-2021

Figure 85: Medical Devices Clinical Trials Count by Trial Status, UK, 2019-2021

Figure 86: Medical Devices Clinical Trials Count by Device Category, UK, 2019-2021

Figure 87: Medical Devices Clinical Trials Count by Indication, UK, 2019-2021

Figure 88: Top Five Medical Devices Clinical Trials Sponsors by Count, UK, 2019-2021

Figure 89: Number of Publicly Owned Hospitals, UK, 2012-2018

Figure 90: Number of Diagnostic Equipment (Absolute Units per 1000 Population), UK, 2015-2021

Figure 91: Publicly Owned Hospital Beds (per 1,000 Population), UK, 2012-2019

Figure 92: Hospital Beds (per 1,000 Population), UK, 2012-2019

Figure 93: Psychiatric Care Hospital Beds (per 1,000 Population), UK, 2012-2019

Figure 94: Life Expectancy at Birth (Years), UK, 2012-2018

Figure 95: Immunization Rate (%), UK, 2013-2019

Figure 96: PM2.5 (µg per m3), UK, 2010-2017

Figure 97: CO2 Emissions (Mt CO2), UK, 2010-2019

Figure 98: Physicians (per 1,000 Population), US, 2010-2019

Figure 99: Dentists (per 1,000 Population), UK, 2012-2019

Figure 100: Pharmacists (per 1,000 Population), UK, 2012-2019

Figure 101: Nurses (per 1,000 Population), UK, 2012-2018

Figure 102: Major Causes of Mortality (Number of Deaths per 100,000 Population), UK, 2019

Figure 103: Major Causes of Male Mortality (Number of Deaths per 100,000 Population) UK, 2019

Figure 104: Major Causes of Female Mortality (Number of Deaths per 100,000 Population) UK, 2019

Figure 105: Disability-Adjusted Life Years by Major Disease (DALYS per 100,000 Population), UK, 2019

Figure 106: Healthcare Expenditure as Percentage of GDP (%), UK, 2010-2019

Figure 107: Healthcare Spending (Government versus Private), UK, 2010-2019

Figure 108: Healthcare Expenditure Components by Function (% of Total Health Expenditure), UK, 2018

Figure 109: Pharmaceutical Spending ($ per Capita), UK, 2010-2018

Figure 110: Opportunities and Challenges

Frequently asked questions

United Kingdom (UK) – Healthcare, Regulatory and Reimbursement Landscape standard reports

Currency USD

Single User

$1,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

United Kingdom (UK) – Healthcare, Regulatory and Reimbursement Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports

Pharmaceuticals

New

Global M&A Deals in H1 2026 - Top Themes by…

Pharmaceuticals

New

Pharmaceutical Drug Development Annual Review 2025

Pharmaceuticals

New

Q2 2026 CRO Activity and Intel Report

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at United Kingdom (UK) – Healthcare, Regulatory and Reimbursement Landscape in real time.

Access a live United Kingdom (UK) – Healthcare, Regulatory and Reimbursement Landscape dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

United Kingdom (UK) – Healthcare, Regulatory and Reimbursement Landscape

Scope

Reasons to Buy

Table of Contents

Table

Figures

Frequently asked questions

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports